Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp registers the resale of up to 859,609 ordinary shares by identified selling shareholders, consisting of up to 399,020 shares issuable upon new warrants and placement agent warrants and up to 446,623 shares issuable upon conversion of amounts under a sponsor promissory note. The registration statement notes shareholders’ approval and the effective date of this registration affect when the new warrants and placement agent warrants become exercisable. The company will receive no proceeds from the resale by the selling shareholders but may receive proceeds if holders exercise warrants for cash at exercise prices of $5.00 and $6.25 per share.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp files a shelf registration to register the resale by selling shareholders of up to 859,609 ordinary shares, comprising up to 399,020 shares issuable upon new warrants, 13,966 placement agent warrant shares and up to 446,623 shares issuable upon conversion of the Sponsor Promissory Note.
The prospectus states the company will receive no proceeds from sales by the selling shareholders, though it may receive cash proceeds if warrants are exercised for cash. The filing discloses recent financings (an inducement warrant exercise raising ~$1.0M, ATM sales of ~$1.75M net aggregate through June 10, 2026), a 1-for-10 reverse split in May 2026, restored Nasdaq shareholders' equity compliance above the $2.5M minimum, and ongoing Nasdaq monitoring until September 23, 2026.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.
Horenshtein Hadar Mirit reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that its CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 7,500 fully vested restricted share units that were immediately settled into ordinary shares, at a stated price of $0.00 per share, for service as an officer. Following this award, the reporting person directly holds 12,515 ordinary shares. A prior 1-for-10 reverse share split on May 28, 2026 adjusted earlier beneficial holdings from 50,146 ordinary shares at $0.0135 par value to 5,015 ordinary shares at $0.135 par value before this grant.
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Silexion Therapeutics Corp is asking shareholders to approve two ordinary resolutions at an extraordinary general meeting on a July date: (1) permit the exercisability of 399,020 new investor warrants (Series C/D) at $5.00 and 13,966 placement agent warrants at $6.25, issued in a May 18, 2026 Warrant Inducement Transaction; and (2) increase authorized share capital from US$796,500 (5,900,000 shares) by an additional unspecified number of ordinary shares. The company states the May transactions and related share issuances restored shareholders’ equity to $2.6M, above the Nasdaq Equity Standard minimum of $2.5M, and that exercising all new warrants could raise approximately $1.995M and $87.3k, respectively. The Board unanimously recommends FOR both proposals. Voting and virtual attendance instructions appear in the proxy materials.
Moringa Sponsor, LP and related parties filed Amendment No. 2 to their Schedule 13D on Silexion Therapeutics Corp. They report beneficial ownership of 1,382,346 ordinary shares, representing 32.99% of Silexion’s ordinary shares outstanding, calculated using 4,189,954 shares reported in Silexion’s Form 10-Q as of March 31, 2026.
The reported holdings include 6,970 ordinary shares, 372 ordinary shares underlying warrants, 450,000 ordinary shares issued on September 15, 2025 upon conversion of $1.8 million under an Amended and Restated Promissory Note, and 925,004 ordinary shares issued on May 14, 2026 upon conversion of $0.4 million under the same note. The reporting persons state they are filing out of an abundance of caution and expressly dispute the validity of the 450,000 and 925,004 shares and do not concede beneficial ownership of them.
Silexion Therapeutics Corp has implemented a 1-for-10 reverse share split of its ordinary shares to help maintain compliance with Nasdaq’s minimum bid price requirements. The split became effective after the close of business on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026 under the existing symbol SLXN.
Following the reverse split, authorized share capital remains at $796,500, now divided into 5,900,000 ordinary shares with par value increasing from $0.0135 to $0.135 per share. As of April 7, 2026, issued shares were consolidated from 4,074,710 to 407,471. The company also adjusted its public and private warrants so each whole warrant now reflects the 1-for-10 ratio and carries an exercise price of $15,525.00 per ordinary share, with no fractional shares issued on exercise.